Convatec Group (LON:CTEC) Insider Jens Viebke Purchases 24,400 Shares of Company Stock

Convatec Group PLC (LON:CTEC) insider Jens Viebke bought 24,400 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average cost of GBX 230 per share, with a total value of £56,120.

Convatec Group Price Performance

Shares of LON CTEC opened at GBX 235.60 on Wednesday. The firm has a 50-day simple moving average of GBX 223.19 and a 200-day simple moving average of GBX 217.57. The stock has a market capitalization of £4.52 billion, a price-to-earnings ratio of 38.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.77. The company has a quick ratio of 0.96, a current ratio of 1.93 and a debt-to-equity ratio of 121.83. Convatec Group PLC has a 52 week low of GBX 193 and a 52 week high of GBX 259.30.

Analysts Set New Price Targets

Several brokerages recently issued reports on CTEC. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 315 price objective on shares of Convatec Group in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 315 price objective on shares of Convatec Group in a report on Wednesday, August 5th. Berenberg Bank lowered their target price on Convatec Group from GBX 340 to GBX 335 and set a “buy” rating on the stock in a report on Friday, September 11th. Jefferies Financial Group restated a “buy” rating and issued a GBX 300 price target on shares of Convatec Group in a research report on Wednesday, August 5th. Finally, Peel Hunt reaffirmed an “add” rating and issued a GBX 270 price target on shares of Convatec Group in a report on Tuesday, August 4th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of GBX 305.44.

About Convatec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.